Skip to main content

Advertisement

Table 1 Characteristics of neurological toxicity during or after first-line chemotherapy with carboplatin plus paclitaxel

From: Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Neurological toxicity No. of patients %
A. during chemotherapy (n = 120)   
   No toxicity 55 (46%)
   At least grade 1 toxicity 65 (54%)
Type of toxicity   
Sensory, grade 1 51 (42%)
Sensory, grade 2 13 (11%)
Sensory, grade 3 1 (1%)
Motor, grade 1 (combined with sensory) 3 (3%)
B. residual toxicity after chemotherapy (n = 60 - 5 patients lost)   
   No toxicity at the moment of interview 46 (77%)
Time to recovery from residual neuropathy   
< 2 months after the end of chemotherapy 22 37%
≥ 2 < 6 months after the end of chemotherapy 15 25%
≥ 6 months after the end of chemotherapy 9 15%
   At least grade 1 residual toxicity at the moment of interview 14 (23%)
Type of residual toxicity   
Sensory, grade 1 12 (20%)
Sensory, grade 2 2 (3%)
Motor, grade 1 (combined with sensory) 3 (5%)